Tratamiento de la diabetes tipo 2 en adultos mayores
Management of type 2 diabetes mellitus in older adults.
Kim KS, Kim SK, Sung KM, Cho YW, Park SW.
Department of Internal Medicine, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Korea.
Diabetes Metab J. 2012 Oct;36(5):336-44. doi:10.4093/dmj.2012.36.5.336.
Abstract
In the near future, the majority of patients with diabetes will be adults aged 65 or older. Unlike young adults with diabetes, elderly diabetic people may be affected by a variety of comorbid conditions such as depression, cognitive impairment, muscle weakness (sarcopenia), falls and fractures, and physical frailty. These geriatric syndromes should be considered in the establishment of treatment goals in older adults with diabetes. Although there are several guidelines for the management of diabetes, only a few are specifically designed for the elderly with diabetes. In this review, we present specific conditions of elderly diabetes which should be taken into account in the management of diabetes in older adults. We also present advantages and disadvantages of various glucose-lowering agents that should be considered when choosing a proper regimen for older adults with diabetes.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3486979/pdf/dmj-36-336.pdf
Fármacos actuales y consideraciones anestésicas para la diabetes mellitus
Current therapeutic agents and anesthetic considerations for diabetes mellitus.
Kang H.
Department of Anesthesiology and Pain Medicine, Eulji General Hospital, Eulji University, Seoul, Korea.
Korean J Anesthesiol. 2012 Sep;63(3):195-202. doi: 10.4097/kjae.2012.63.3.195.
Abstract
As the incidence of diabetes mellitus (DM) continues to increase worldwide, more diabetic patients will be presented for surgery and anesthesia. This increase of DM is a consequence of the rise in new patients of type 2 DM, and is likely attributable to rapid economic development, improved living standards, aging population, obesity, and lack of exercise. The primary goal of management in DM is to delay, or prevent the macro- and microvascular complications by achieving good glycemic control. More understanding of the pathophysiology of DM has contributed to the advance of new pharmacological approaches. In addition to the conventional therapy for DM, glucagon-like peptide-1 (GLP-1) mimetics, dipeptidyl peptidase-4 (DPP-4) inhibitors, thiazolidinediones (TZDs), and insulin analogues are currently available effective hypoglycemic agents for the management of the patients with DM in the perioperative period and also consider the adverse effects of newly introduced agents that need more clinical observations.
http://ekja.org/Synapse/Data/PDFData/0011KJAE/kjae-63-195.pdf
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3460146/pdf/kjae-63-195.pdf
Atentamente
Anestesiología y Medicina del Dolor
www.anestesia-dolor.org
Management of type 2 diabetes mellitus in older adults.
Kim KS, Kim SK, Sung KM, Cho YW, Park SW.
Department of Internal Medicine, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Korea.
Diabetes Metab J. 2012 Oct;36(5):336-44. doi:10.4093/dmj.2012.36.5.336.
Abstract
In the near future, the majority of patients with diabetes will be adults aged 65 or older. Unlike young adults with diabetes, elderly diabetic people may be affected by a variety of comorbid conditions such as depression, cognitive impairment, muscle weakness (sarcopenia), falls and fractures, and physical frailty. These geriatric syndromes should be considered in the establishment of treatment goals in older adults with diabetes. Although there are several guidelines for the management of diabetes, only a few are specifically designed for the elderly with diabetes. In this review, we present specific conditions of elderly diabetes which should be taken into account in the management of diabetes in older adults. We also present advantages and disadvantages of various glucose-lowering agents that should be considered when choosing a proper regimen for older adults with diabetes.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3486979/pdf/dmj-36-336.pdf
Fármacos actuales y consideraciones anestésicas para la diabetes mellitus
Current therapeutic agents and anesthetic considerations for diabetes mellitus.
Kang H.
Department of Anesthesiology and Pain Medicine, Eulji General Hospital, Eulji University, Seoul, Korea.
Korean J Anesthesiol. 2012 Sep;63(3):195-202. doi: 10.4097/kjae.2012.63.3.195.
Abstract
As the incidence of diabetes mellitus (DM) continues to increase worldwide, more diabetic patients will be presented for surgery and anesthesia. This increase of DM is a consequence of the rise in new patients of type 2 DM, and is likely attributable to rapid economic development, improved living standards, aging population, obesity, and lack of exercise. The primary goal of management in DM is to delay, or prevent the macro- and microvascular complications by achieving good glycemic control. More understanding of the pathophysiology of DM has contributed to the advance of new pharmacological approaches. In addition to the conventional therapy for DM, glucagon-like peptide-1 (GLP-1) mimetics, dipeptidyl peptidase-4 (DPP-4) inhibitors, thiazolidinediones (TZDs), and insulin analogues are currently available effective hypoglycemic agents for the management of the patients with DM in the perioperative period and also consider the adverse effects of newly introduced agents that need more clinical observations.
http://ekja.org/Synapse/Data/PDFData/0011KJAE/kjae-63-195.pdf
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3460146/pdf/kjae-63-195.pdf
Atentamente
Anestesiología y Medicina del Dolor
www.anestesia-dolor.org
No hay comentarios:
Publicar un comentario